IN2015MN00038A - - Google Patents
Info
- Publication number
- IN2015MN00038A IN2015MN00038A IN38MUN2015A IN2015MN00038A IN 2015MN00038 A IN2015MN00038 A IN 2015MN00038A IN 38MUN2015 A IN38MUN2015 A IN 38MUN2015A IN 2015MN00038 A IN2015MN00038 A IN 2015MN00038A
- Authority
- IN
- India
- Prior art keywords
- formulations
- infection
- anthrax
- vaccine
- antigen
- Prior art date
Links
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000193738 Bacillus anthracis Species 0.000 abstract 1
- 101710194807 Protective antigen Proteins 0.000 abstract 1
- 208000022338 anthrax infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664062P | 2012-06-25 | 2012-06-25 | |
| US201361801385P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047712 WO2014004578A1 (en) | 2012-06-25 | 2013-06-25 | Temperature stable vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00038A true IN2015MN00038A (enExample) | 2015-10-16 |
Family
ID=49783811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN38MUN2015 IN2015MN00038A (enExample) | 2012-06-25 | 2013-06-25 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150335752A1 (enExample) |
| EP (1) | EP2863898A4 (enExample) |
| JP (1) | JP2015525748A (enExample) |
| KR (1) | KR20150034170A (enExample) |
| CN (1) | CN104470506A (enExample) |
| AU (1) | AU2013280480B2 (enExample) |
| CA (1) | CA2877130A1 (enExample) |
| HK (1) | HK1207312A1 (enExample) |
| IL (1) | IL236380A0 (enExample) |
| IN (1) | IN2015MN00038A (enExample) |
| RU (1) | RU2014151424A (enExample) |
| SG (1) | SG11201408262XA (enExample) |
| WO (1) | WO2014004578A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015100344A1 (en) * | 2013-12-27 | 2015-07-02 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| IL310015B1 (en) * | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| US20170007690A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilization of anthrax recombinant protective antigen |
| WO2017007835A1 (en) | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for nanoemulsion vaccine formulations |
| EP3319930A4 (en) * | 2015-07-07 | 2019-04-10 | NanoBio Corporation | METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS |
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| US20190216925A1 (en) * | 2016-09-16 | 2019-07-18 | Leukocare Ag | A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing |
| EP3512939A1 (en) | 2016-09-16 | 2019-07-24 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188171C (zh) * | 1994-06-02 | 2005-02-09 | 廓德伦特控股剑桥有限公司 | 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物 |
| US7201912B2 (en) * | 2002-04-12 | 2007-04-10 | Emergent Biodefense Operation Lansing Inc. | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
| JO3324B1 (ar) * | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| CN100556400C (zh) * | 2006-07-20 | 2009-11-04 | 上海交通大学 | 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法 |
| WO2008079464A2 (en) * | 2006-09-08 | 2008-07-03 | Becton, Dickinson And Company | Stable powder formulations of alum-adsorbed vaccines |
| EP2829282B1 (en) * | 2007-03-22 | 2017-10-25 | The Regents of The University of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| US8778359B2 (en) * | 2008-07-30 | 2014-07-15 | Emergent Biosolutions Inc. | Stable anthrax vaccine formulations |
| US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| JP2012515752A (ja) * | 2009-01-22 | 2012-07-12 | ファーマシーネ，インコーポレイテッド | 安定なワクチン組成物とその使用方法 |
-
2013
- 2013-06-25 EP EP13809706.8A patent/EP2863898A4/en not_active Withdrawn
- 2013-06-25 SG SG11201408262XA patent/SG11201408262XA/en unknown
- 2013-06-25 RU RU2014151424A patent/RU2014151424A/ru not_active Application Discontinuation
- 2013-06-25 KR KR20157000755A patent/KR20150034170A/ko not_active Withdrawn
- 2013-06-25 IN IN38MUN2015 patent/IN2015MN00038A/en unknown
- 2013-06-25 AU AU2013280480A patent/AU2013280480B2/en not_active Ceased
- 2013-06-25 CA CA2877130A patent/CA2877130A1/en not_active Abandoned
- 2013-06-25 CN CN201380037918.7A patent/CN104470506A/zh active Pending
- 2013-06-25 WO PCT/US2013/047712 patent/WO2014004578A1/en not_active Ceased
- 2013-06-25 HK HK15108032.6A patent/HK1207312A1/xx unknown
- 2013-06-25 US US14/410,942 patent/US20150335752A1/en not_active Abandoned
- 2013-06-25 JP JP2015520412A patent/JP2015525748A/ja not_active Withdrawn
-
2014
- 2014-12-21 IL IL236380A patent/IL236380A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2863898A1 (en) | 2015-04-29 |
| WO2014004578A1 (en) | 2014-01-03 |
| RU2014151424A (ru) | 2016-08-20 |
| KR20150034170A (ko) | 2015-04-02 |
| CA2877130A1 (en) | 2014-01-03 |
| CN104470506A (zh) | 2015-03-25 |
| US20150335752A1 (en) | 2015-11-26 |
| SG11201408262XA (en) | 2015-01-29 |
| IL236380A0 (en) | 2015-02-26 |
| AU2013280480B2 (en) | 2018-03-15 |
| EP2863898A4 (en) | 2016-04-27 |
| HK1207312A1 (en) | 2016-01-29 |
| AU2013280480A1 (en) | 2015-01-22 |
| JP2015525748A (ja) | 2015-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00038A (enExample) | ||
| MX2013007657A (es) | Oligodesoxinucleotidos inmunoestimulantes. | |
| MX2017015881A (es) | Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas. | |
| MY168959A (en) | Vaccine compositions for the prevention of dengue virus infection | |
| PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
| MX2013013800A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
| HUE046334T2 (hu) | Mikrobális oltóanyagok és azokat tartalmazó trágyakészítmények | |
| MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| BR112013003772A2 (pt) | composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| EP2825196A4 (en) | ADJUVANZ AND VACCINE COMPOSITIONS | |
| HUE044841T2 (hu) | TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai | |
| BR112014014078A8 (pt) | composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de uso dos mesmos | |
| NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
| EA201590491A1 (ru) | Иммуногенная композиция | |
| WO2013006569A3 (en) | Herpes virus vaccine and methods of use | |
| JO3362B1 (ar) | الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان | |
| NZ630831A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| NZ715459A (en) | A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same | |
| HUE065746T2 (hu) | Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| WO2010053610A3 (en) | Stable anthrax vaccine formulations | |
| MX373395B (es) | Vacuna de haemophilus parasuis para serovar tipo cuatro. | |
| IN2015KN00516A (enExample) | ||
| EA201491845A1 (ru) | Получение стерильных активных фармацевтических ингредиентов |